Clinical Trial Update: Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating the PET radiotracer [18F] FMH3 to assess histamine-3 receptor activity in Alzhei…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [18F] FMH3

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Alzheimer Disease | EARLY_Phase 1 | Status: COMPLETED